

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6313194

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	SANGART, INC.	07/18/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	WILLIAM SCHINDLER	
<b>Street Address:</b>	40 EAST WILDFLOWER DRIVE	
<b>City:</b>	SANTA FE	
<b>State/Country:</b>	NEW MEXICO	
<b>Postal Code:</b>	87506	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	14777261	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(314)612-7690	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	3144447600	
<b>Email:</b>	ipdept@lewisrice.com	
<b>Correspondent Name:</b>	LEWIS RICE LLC	
<b>Address Line 1:</b>	600 WASHINGTON AVENUE, SUITE 2500	
<b>Address Line 2:</b>	BOX IP DEPARTMENT	
<b>Address Line 4:</b>	ST. LOUIS, MISSOURI 63101	
<b>ATTORNEY DOCKET NUMBER:</b>	SNT/132.USN	
<b>NAME OF SUBMITTER:</b>	CHRISTIE PADDOCK	
<b>SIGNATURE:</b>	/Christie Paddock/	
<b>DATE SIGNED:</b>	09/23/2020	
<b>Total Attachments: 17</b>		
source=Executed Assignment from Sangart to William Schindler to be recorded#page1.tif		
source=Executed Assignment from Sangart to William Schindler to be recorded#page2.tif		
source=Executed Assignment from Sangart to William Schindler to be recorded#page3.tif		
source=Executed Assignment from Sangart to William Schindler to be recorded#page4.tif		
source=Executed Assignment from Sangart to William Schindler to be recorded#page5.tif		

source=Executed Assignment from Sangart to William Schindler to be recorded#page6.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page7.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page8.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page9.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page10.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page11.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page12.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page13.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page14.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page15.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page16.tif  
source=Executed Assignment from Sangart to William Schindler to be recorded#page17.tif

## ASSIGNMENT AGREEMENT

This Assignment Agreement ("Agreement") is entered into by and between Sangart, Inc. ("Sangart") and William Schindler ("Schindler") and is effective as of July 18, 2014 ("Effective Date").

NOW THEREFORE, in consideration of the premises, covenants and representations set forth herein, and for other good and valuable consideration, the sufficiency of which are hereby acknowledged, the parties agree as follows:

### 1. Definitions.

1.1. "Assigned Assets" means, collectively (a) Know-How, (b) Patent Rights and Other IP, in each case that is owned by Sangart as of the Effective Date, including the Patent Rights that are listed on Exhibit A, and (c) Records and Data. Assigned Assets exclude contracts and agreements, employment records and other human resource-related materials, financial records, budgets and projections and any interest in real property, any capital equipment and all other Sangart business records other than the Records and Data.

1.2. "Know-How" means all inventions, creations, discoveries, models, technology, compositions, formulas, designs, devices, formulations, methods, processes, materials, know-how, studies, data, reports, trade secrets and other information that was or is invented, created, discovered, generated or derived by or on behalf of Sangart on or prior to the Effective Date.

1.3. "Other IP" means all of the following and similar intangible property and related proprietary rights, interests and protections, however arising, pursuant to the laws of any jurisdiction throughout the world: (a) original works of authorship in any medium of expression, whether or not published, all copyrights (whether registered or unregistered), all registrations and applications for registration of such copyrights, and all issuances, extensions and renewals of such registrations and applications; and (b) trademarks, service marks, trade names, drug names, brand names, logos, trade dress and other proprietary indicia of goods and services, whether registered or unregistered, and all registrations and applications for registration of such trademarks, including intent-to-use applications, all issuances, extensions and renewals of such registrations and applications and the goodwill connected with the use of and symbolized by any of the foregoing.

1.4. "Patent Rights" means patents and patent applications, together with all additions, divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, and renewals of any of the foregoing, and all foreign applications and patents corresponding to any of the foregoing.

1.5. "Records and Data" means originals, or where not available, copies, of all books, records, and data, in each case in Sangart's possession as of the Effective Date that relate to, were used in, or were generated in the course of Sangart's research and

development activities, including without limitation all preclinical and clinical data files (electronic and hard copy) and study reports, regulatory files and correspondence, all regulatory submissions and reports, all quality files including but not limited to; all standard operating procedures (SOP) and master batch records, all executed batch records, all stability data and the Novatek stability data management system and database, all technical reports, raw data (including notebooks), logbooks (including the password logbook), and engineering, scale-up and facility design for commercial operations. Records and Data exclude third party records and data except as may be expressly identified in this Section 1.5.

2. Assignment of Assigned Assets. Subject to its receipt of the Fee in full by the payment deadline specified in Section 3 below, Sangart hereby irrevocably grants, sells, transfers, conveys, assigns and delivers to Schindler all of Sangart's right, title and interest in and to the Assigned Assets, together with all causes of action and other rights to sue for and remedies against past, present and future infringements thereof, together with the right to collect damages therefore, and all rights of priority provided thereby, and all rights to seek protection of interest therein under the laws of any jurisdiction worldwide, to have and to hold the same unto Schindler, its successors and assigns, for and during the existence of such rights and all renewals thereof. Schindler shall be free to assign and/or transfer the Assigned Assets, in whole or in part, to any other person or entity, in its sole discretion, without any further obligations to Sangart. It shall be the responsibility of Schindler, or any assignee or transferee, to retrieve all tangible records relating to the Assigned Assets from storage and Sangart shall reasonably cooperate with such effort to the extent of its abilities.

2.1. Inventions. With respect to Know-How owned by Sangart as of the Effective Date and/or patent applications in the Assigned Assets that are being prepared or prosecuted as of the Effective Date, subject to its receipt of the Fee in full by the payment deadline specified in Section 3 below, Sangart also conveys the right to pursue (or to continue to pursue, as applicable) provisional patent applications, patent applications, including all counterparts, divisions, continuations, continuation-in-parts, reexaminations or reissues thereof, throughout the world, together with any and all rights of Sangart in all such Know-How and Patent Rights and all rights of priority provided thereby, and all rights to seek protection of interests therein under the laws of any jurisdiction worldwide and all tangible embodiments thereof, to have and to hold the same under Schindler, his successors and assigns, for and during the existence of such rights and all renewals thereof.

2.2. Further Actions. Subject to its receipt of the Fee in full by the payment deadline specified in Section 3 below, Sangart shall, from time to time, upon the reasonable request of Schindler at Schindler's expense, execute and deliver to Schindler such further documents or instruments of assignment, conveyance, transfer or confirmation and to take such action as may be necessary in order to more effectively convey and transfer the Assigned Assets to, and vest and confirm title to such Assigned Assets in, Schindler. Further, following receipt of the Fee (defined below) has been received, Sangart will give Senniger Powers permission to coordinate with Schindler for

the payment of any annuities on the Patent Rights provided that any such costs shall be borne solely by Schindler.

2.3. Employees. The parties agree that the Assigned Assets do not include any employment agreements. However, subject to its receipt of the Fee in full by the payment deadline specified in Section 3 below, Sangart acknowledges that Schindler or a subsequent assignee of the Assigned Assets may hire one or more people formerly employed by Sangart, and Sangart consents to such hiring to the extent such hiring complies with applicable laws and does not conflict with, result in a breach of, or constitute a default under any agreement to which Sangart is bound, to the extent such consent is required. Except as set forth in Section 3, no payments shall be owed to Sangart in connection with the foregoing.

2.4. Vendors; Government Authorizations. The parties agree that the Assigned Assets do not include any contracts with vendors, service providers, or collaborators. Similarly, the parties agree that the Assigned Assets do not include any government authorizations. However, Sangart acknowledges that Schindler or a subsequent assignee of the Assigned Assets intends to establish relationships with some or all of such vendors, service providers, or collaborators or with applicable governmental authorities, and Sangart consents to such activities, to the extent such consent is required. In particular, Sangart consents to Schindler's or such assignee's use of the same patent attorney(s) used by Sangart to prosecute the patent rights in the Assigned Assets and agrees that the authority to assert and waive attorney-client privilege with respect to past patent prosecution activities shall be transferred to Schindler. Except as set forth in Section 3, no payments shall be owed to Sangart in connection with the foregoing consents.

2.5. No Assumption of Liabilities. As a result of the transactions described herein, Schindler does not assume any liabilities or obligations of Sangart of any kind, whether known or unknown, contingent, matured or otherwise, whether currently existing or hereinafter created ("Excluded Liabilities").

[REDACTED]

3. Consideration.

[REDACTED]

4. Mutual Representations and Warranties. Each party represents and warrants to the other that: (a) in the case of Sangart, it is duly organized, validly existing and in good standing under the laws of its state of incorporation; (b) it has full power and authority to enter into this Agreement and to consummate the transactions contemplated hereby; (c) in

the case of Sangart, its execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action; and (d) this Agreement constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms.

5. Sangart Representations and Warranties. Sangart represents and warrants to Schindler that the statements contained in this Section 5 are true and correct as of the date hereof.

5.1. No Conflicts; Consents. The execution, delivery and performance by Sangart of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the articles of incorporation, by-laws or other organizational documents of Sangart; (b) conflict with or result in a violation or breach of any provision of any law, regulation, or governmental or judicial order applicable to Sangart or the Assigned Assets; (c) require the consent, notice or other action by any person, entity, or governmental authority; or (d) result in the creation or imposition of any mortgage, pledge, lien, charge, security interest, license, claim or other encumbrance on the Assigned Assets.

5.2. Title to Assigned Assets. To the best of its knowledge, Sangart owns and has good title to the Assigned Assets, free and clear of any mortgage, pledge, lien, charge, security interest, license, claim or other encumbrance, [REDACTED]

5.3. Patents. To the knowledge of Sangart, Exhibit A is a complete and accurate list of the Patent Rights in the Assigned Assets. To the knowledge of Sangart, there are no claims pending or threatened by any person or entity with respect to the ownership, validity or enforceability of any such Patent Rights.

5.4. Infringement. To the knowledge of Sangart, Sangart's prior and current use of the Assigned Assets has not infringed, violated or misappropriated, and does not infringe, violate or misappropriate, the intellectual property of any person or entity. Sangart has not received any communication, and no suit or action has been instituted, settled or, to Sangart's knowledge, threatened that alleges any such infringement, violation or misappropriation. To the knowledge of Sangart, no person or entity has infringed, violated or misappropriated, or is infringing, violating, or misappropriating, any Patent Rights or other intellectual property in the Assigned Assets. Sangart has not made or asserted any claim, demand or notice against any person or entity alleging any such infringement, misappropriation or other violation.

5.5. Brokers. No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the transactions

contemplated by this Agreement based upon arrangements made by or on behalf of Sangart.

6. Disclaimer. EXCEPT AS SET FORTH IN SECTIONS 4 AND 5, AND TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW, THE ASSIGNED ASSETS ARE CONVEYED TO SCHINDLER "AS IS" AND SANGART MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, IN RESPECT OF THE ASSIGNED ASSETS, INCLUDING WITHOUT LIMITATION WITH RESPECT TO VALIDITY, ENFORCEABILITY, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR THAT THE PRACTICE THEREOF WILL NOT INFRINGE THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, OR THAT ANY PATENT WILL ISSUE, AND ANY SUCH REPRESENTATIONS OR WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED BY SANGART AND WAIVED BY SCHINDLER. Schindler acknowledges that Sangart has no obligation to initiate any litigation in relation to the Assigned Assets, or to defend any action brought by any third party challenging the validity or enforceability of any of the Assigned Assets.

7. Indemnification. Schindler shall defend, indemnify and hold harmless Sangart and its affiliates and its and their employees, directors, officers, agents, successors, assigns and heirs in full from and against any and all claims, liabilities, loss, damages, expenses (including legal expenses) and costs and any consequential, indirect or economic loss awarded against or incurred or paid by any of the foregoing persons or entities as a result of or in connection with (i) the practice or use of the Assigned Assets by Schindler or any person or entity authorized by Schindler; and/or (ii) any product or service based upon, using, or covered by the Assigned Assets. Sangart shall defend, indemnify and hold harmless Schindler from and against any and all claims, liabilities, loss, damages, expenses (including legal expenses) and costs and any consequential, indirect or economic loss awarded against or incurred or paid as a result of or in connection with any Excluded Liabilities and/or any breach of any representation or warranty of Sangart in this Agreement. Notwithstanding any other term in this Section 7 or in this Agreement, Sangart's total indemnification obligation to Schindler shall not exceed the Fee received by Sangart, and Schindler's total indemnification obligation to Sangart shall not exceed an amount equal to the Fee paid by Schindler.


8. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, excluding its conflicts of laws principles. The exclusive jurisdiction for any action relating to this Agreement shall be a federal or state court in the State of California and the parties consent to such jurisdiction and waive and agree not to plead or claim that any such action or proceeding has been brought in an inconvenient forum.

9. Miscellaneous. No changes or modifications or waivers are to be made to this Agreement unless evidenced in writing and signed for and on behalf of both parties. If any provision of this Agreement shall be determined to be illegal or unenforceable, that provision will be limited or eliminated to the minimum extent necessary so that this

Agreement shall otherwise remain in full force and effect and enforceable. Headings herein are for convenience of reference only and shall in no way affect interpretation of the Agreement. This Agreement sets forth the entire understanding and agreement between the parties as to the subject matter of this Agreement and supersedes, cancels and merges all prior agreements, negotiations, commitments, communications and discussions between the parties as to the subject matter hereof.

IN WITNESS WHEREOF, each party has executed this Agreement as of the Effective Date.

Sangart, Inc.

By:   
Name: David Remas  
Title: CFO


 7/18/14  
William Schindler

Exhibit A  
Assigned Patent Rights

<i>Title</i>	<i>Status</i>	<i>Country</i>	<i>Application #</i>	<i>File Date</i>	<i>Publication #</i>	<i>Patent #</i>	<i>File Type</i>	<i>File Reference No. SP SNT#</i>
<b>Patent Family #4</b>								
Method for production of stroma-free hemoglobin	Converted	US	60/104,319	10/15/1998			Provisional	981.USP1
Method for production of stroma-free hemoglobin	Converted	US	60/122,180	3/1/1999			Provisional	981.USP2
Method for production of stroma-free hemoglobin	Issued	US	09/807,565	4/12/2001		6,773,613	National (PCT)	981.USN
Method for production of stroma-free hemoglobin	Converted	WO	PCT/US99/24149	10/15/1999	WO 00/21591		PCT	981.WO
<b>Patent Family #5</b>								
Methods and compositions for oxygen transport comprising modified hemoglobin in plasma	Converted	US	60/347,733	1/11/2002			Provisional	021.USP1
Methods and compositions for oxygen transport comprising modified hemoglobin in plasma	Issued	US	10/501,171	7/9/2004	2005-0020485	7,271,145	National (PCT)	021.USN
Methods and compositions for oxygen transport comprising modified hemoglobin in plasma	Converted	WO	PCT/US03/00595	1/10/2003	WO 03/059286		PCT	021.WO
<b>Patent Family #7</b>								
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Converted	US	60/347,741	1/11/2002			Provisional	023.USP1
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	US	10/340,141	1/10/2003	2003-0162693	6,844,317	Utility CIP	023.USCP1

<i>Title</i>	<i>Status</i>	<i>Country</i>	<i>Application #</i>	<i>File Date</i>	<i>Publication #</i>	<i>Patent #</i>	<i>File Type</i>	<i>File Reference No. SP SNT#</i>
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	US	10/925,067	8/24/2004	2006-0026816	6,974,795	Utility CON	023.USCN
Method For Making a High Oxygen Affinity Modified Hemoglobin For Oxygen Transport	Issued	US	11/717,364	3/13/2007	2007-0167352	7,625,862	Utility CON	023.USCN2
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	US	12/625,900	11/25/2009	2010-0105606	7,989,414	Utility CON	023.USCN3
Methods for making high oxygen affinity modified hemoglobin for oxygen transport	Issued	US	13/180,291	7/11/2011	2012-0004396	8,377,866	CON	023.USCN4
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Converted	WO	PCT/US03/00696	1/10/2003	WO 03/059363		PCT	023.WO
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Pending	BR	PI0306846-3	1/10/2003	PI0306846-3		National (PCT)	023.BR
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	CA	2473662	1/10/2003	2473662	2,473,862	National (PCT)	023.CA
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Published	CN	201310091021.4	1/10/2003	103203013		Divisional	023.CNDV1
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Pending	EG	668/2003	1/10/2003			National (PCT)	023.EG

<i>Title</i>	<i>Status</i>	<i>Country</i>	<i>Application #</i>	<i>File Date</i>	<i>Publication #</i>	<i>Patent #</i>	<i>File Type</i>	<i>File Reference No. SP SNT#</i>
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	AT	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPAT
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	BE	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPBE
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	BG	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPBG
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	CH	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPCH
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	CZ	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPCZ
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	DE	03705713.0	1/10/2003	EP1465643	60318388	EPC	023.EPDE
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	DK	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPDK
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	EE	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPEE
Methods and compositions for oxygen transport comprising a high oxygen affinity	Issued	ES	03705713.0	1/10/2003	EP1465643	2299686	EPC	023.EPES

<i>Title</i>	<i>Status</i>	<i>Country</i>	<i>Application #</i>	<i>File Date</i>	<i>Publication #</i>	<i>Patent #</i>	<i>File Type</i>	<i>File Reference No. SP SNT#</i>
modified hemoglobin								
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	FI	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPFI
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	FR	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPFR
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	GB	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPGB
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	GR	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPGR
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	IE	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPIE
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	IT	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPIT
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	LI	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPLI
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	NL	03705713.0	1/10/2003	EP1465643	1,465,643	EPC	023.EPNL

<i>Title</i>	<i>Status</i>	<i>Country</i>	<i>Application #</i>	<i>File Date</i>	<i>Publication #</i>	<i>Patent #</i>	<i>File Type</i>	<i>File Reference No. SP SNT#</i>
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	SE	03705713.0	1/10/2003	EP1485643	1,455,843	EPC	023.EPSE
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Published	EP	07022374.8	1/10/2003	1894573		Divisional	023.EPDV1
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	ID	W-00 2004.01456	1/10/2003	040,529	ID P0026172	National (PCT)	023.ID
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	IN	1528/CHENP/2004	1/10/2003		232,203	National (PCT)	023.IN
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Pending	IN	TBA	1/10/2003			Divisional	023.INDV1
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	JP	2003-559525	1/10/2003	2006-515225T	5149480	National (PCT)	023.JP
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	KR	10-2004-7010847	1/10/2003		964,604	National (PCT)	023.KR
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin	Issued	MX	PA/a/2004/006733	1/10/2003	PA0400673	259,351	National (PCT)	023.MX

Patent Family #10								
Methods to enhance hemodynamic stability using oxygen carrying compositions	Converted	US	60/605,816	8/31/2004			Provisional	042.USP1
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	US	12/260,945	10/29/2008	2009/0075866	7,622,439	Utility CON	042.USCN1
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	US	12/623,760	11/23/2009	2010-0087361	8,278,275	CON	042.USCN2
Methods to enhance hemodynamic stability using oxygen carrying compositions	Converted	WO	PCT/US2005/31257	8/30/2005	WO 06/026739		PCT	042.WO
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	AU	2005279780	8/30/2005	2005279780	2005279780	National (PCT)	042.AU
Methods to enhance hemodynamic stability using oxygen carrying compositions	Pending	BR	PI0514713-1	8/30/2005	PI0514713-1		National (PCT)	042.BR
Methods to enhance hemodynamic stability using oxygen carrying compositions	Pending	CA	2578232	8/30/2005	2578232		National (PCT)	042.CA
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	BE	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPBE
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	CH	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPCH
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	DE	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPDE
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	ES	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPES
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	FR	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPFR
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	GB	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPGB

Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	IE	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPIE
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	IT	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPIT
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	LI	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPLI
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	NL	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPNL
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	SE	05799992.2	8/30/2005	1796694	1,796,694	EPC	042.EPSE
Methods to enhance hemodynamic stability using oxygen carrying compositions	Pending	IN	1324/CHENP/2007	8/30/2005				042.IN
Methods to enhance hemodynamic stability using oxygen carrying compositions	Pending	JP	2012-168567	8/30/06/2012			Divisional	042.JPDV1
Methods to enhance hemodynamic stability using oxygen carrying compositions	Issued	MX	MX/a/2007/002187	8/30/2005		285,082	National (PCT)	042.MX
<b>Patent Family #12</b>								
Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissues using heme proteins as carriers	Converted	US	60/655,137	3/7/2005			Provisional	051.USP1
MalPEG-Hb conjugate-containing compositions for delivering carbon monoxide (CO) to cells	Pending	US	13/276,992	10/19/2011	2012-0094912		Utility CON	051.USCN2
MalPEG-Hb conjugate-containing compositions for delivering nitric oxide (NO) to cells	Pending	US	13/277,003	10/19/2011	2012-0094936		Utility CON	051.USCN3
Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissues using heme proteins as carriers	Converted	WO	PCT/US06/08257	3/7/2005				051.WO

Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissues using heme proteins as carriers	Issued	AU	2006220548	3/7/2006		2006220548	National (PCT)	051.AU
Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissues using heme proteins as carriers	Pending	EP	06737428.0	3/7/2006	1,863,603			051.EP
<b>Patent Family #14</b>								
Method For Making Polyalkylene Oxide Modified Hemoglobin	Converted	US	61/099,092	9/22/2008			Provisional	081.USP1
Method For Making Polyalkylene Oxide Modified Hemoglobin	Issued	US	12/536,842	8/6/2009	2010-0075379-A1	8,021,858	Utility	081.US
<b>Patent Family #16</b>								
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Converted	US	61/308,238	2/25/2010			Provisional	101.USP1
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Converted	WO	PCT/US11/25888	2/23/2011	WO 2011/106396		PCT	101.WO
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Pending	AU	2011220885	2/23/2011	2011220885		National (PCT)	101.AU
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Pending	CA	2791122	2/23/2011	2791122		National (PCT)	101.CA
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Pending	CN	201180011267.5	2/23/2011	102859364		National (PCT)	101.CN
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Pending	EP	11747978.2	2/23/2011	2539715		National (PCT)	101.EP
Methods For Preparing PEG-Hemoglobin Conjugates Using	Pending	HK	13104052.2	2/23/2011			National (PCT)	101.HK

Reduced Reactant Ratios								
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Pending	IN	8035/CHENP/2012	2/23/2011			National (PCT)	101.IN
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Pending	JP	2012-555105	2/23/2011	2013-520512		National (PCT)	101.JP
Methods For Preparing PEG-Hemoglobin Conjugates Using Reduced Reactant Ratios	Pending	KR	2012-7025030	2/23/2011			National (PCT)	101.KR
<b>Patent Family #17</b>								
Methods for Preparing Stable Deoxygenated Peg-Conjugated Hemoglobin Solutions	Converted	US	61/379,536	9/2/2010			Provisional	102.USP1
Methods for Preparing Stable Deoxygenated Peg-Hemoglobin Conjugate Solutions Comprising an Antioxidant	Issued	US	13/224,084	5/1/2011	2012-0059153	8,608,815	Utility	102.US
<b>Patent Family #18</b>								
Methods For Preserving An Organ To Be Transplanted Using A Hemoglobin Based Carbon Monoxide Carrier	Converted	US	61/438,832	2/2/2011			Provisional	111.USP1
Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex	Pending	US	13/363,565	2/1/2012	2012-0196270		Utility	111.US
<b>Patent Family #21</b>								
Method of delivering oxygen, carbon monoxide or mixtures thereof using high oxygen affinity hemoglobin with enhanced nitrite reductase activity	Converted	US	61/617,638	3/29/2012			Provisional	121.USP1

Method of delivering oxygen, carbon monoxide or mixtures thereof using high oxygen affinity hemoglobin with enhanced nitrite reductase activity	Published	PCT	PCT/US13/32694	3/15/2013	WO 2013-148375		Utility	121.WO
<b>Patent Family #22</b>								
Compositions and methods for polynitroxylating heme proteins using maleimide-activated nitroxyl compounds	Converted	US	61/619,768	4/3/2012			Provisional	122.USP1
Compositions and methods for polynitroxylating heme proteins using maleimide-activated nitroxyl compounds	Converted	US	61/619,783	4/3/2012			Provisional	122.USP2
Compositions and methods for polynitroxylating heme proteins using maleimide-activated nitroxyl compounds	Published	PCT	PCT/US13/32704	3/15/2013	WO 2013-151776		Utility	122.WO
<b>Patent Family #23</b>								
Packaging system for preserving a nonoxygenated hemoglobin based oxygen therapeutic product	Converted	US	61/797,541	3/15/2013			Provisional	131.USP1
Packaging system for preserving a nonoxygenated hemoglobin based oxygen therapeutic product	Published	US	13/895,751	5/16/2013	2013-0327677		Utility	131.US
<b>Patent Family #24</b>								
Polyalkylene oxide valerate hemoglobin conjugates	Converted	US	61/801,016	3/15/2013			Provisional	132.USP1
Polyalkylene oxide valerate hemoglobin conjugates	Pending	PCT	PCT/US2014/030569	3/17/2014			Utility	132.WO

Exhibit B



See attached